Loading…
Quest Laboratories (QUESTLAB)₹86.30+1.77%Pharmaceuticals
In the Mar 2026 quarter (standalone), Quest Laboratories reported sales of ₹32.35 Cr, down 30.3% from Mar 2025, and net profit of ₹2.86 Cr, up 48.2% year on year. For the year to Mar 2026, sales were ₹112 Cr and net profit ₹14.99 Cr.
Company filings, standalone accounts; latest reported quarter Mar 2026
| Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Sales | 15.22 | 27.33 | 14.83 | 46.39 | 23.16 | 25.60 | 30.56 | 32.35 |
| Expenses | 13.49 | 18.59 | 14.19 | 45.74 | 19.38 | 22.27 | 23.74 | 28.33 |
| Operating Profit | 1.77 | 8.79 | 0.65 | 0.80 | 3.81 | 3.37 | 6.89 | 4.13 |
| OPM % | 11.7% | 32.2% | 4.5% | 1.8% | 16.5% | 13.3% | 22.6% | 12.9% |
| Other Income | 0.15 | 0.67 | 0.29 | 3.40 | 1.84 | 1.41 | 0.56 | −1.30 |
| Interest | 0.12 | 0.36 | 0.03 | 0.36 | 0.63 | 0.57 | 0.46 | 0.15 |
| Depreciation | 0.16 | 0.15 | 0.16 | 0.20 | 0.22 | 0.22 | 0.19 | 0.22 |
| Profit before tax | 1.67 | 8.99 | 0.78 | 3.67 | 4.83 | 4.02 | 6.83 | 2.47 |
| Tax % | 11.5% | 32.5% | 0.0% | 47.3% | 15.0% | 0.0% | 40.9% | −16.6% |
| Net Profit | 1.47 | 6.05 | 0.77 | 1.93 | 4.09 | 4.01 | 4.02 | 2.86 |
| EPS (Rs) | 0.89 | 3.69 | 0.47 | 1.17 | 2.49 | 2.44 | 2.45 | 1.74 |
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|
| Sales | 29.95 | 58.94 | 61.89 | 82.83 | 104 | 112 | 112 |
| Expenses | 29.05 | 53.05 | 54.09 | 67.10 | 88.19 | 94.22 | 93.72 |
| Operating Profit | 0.99 | 5.99 | 7.98 | 15.95 | 15.95 | 17.96 | 18.20 |
| OPM % | 4.7% | 11.1% | 13.0% | 19.1% | 15.0% | 16.1% | 16.3% |
| Other Income | 0.00 | 0.00 | 0.00 | 0.00 | 3.99 | 2.99 | 2.51 |
| Interest | 0.00 | 0.00 | 0.99 | 0.99 | 0.99 | 1.99 | 1.81 |
| Depreciation | 0.00 | 0.00 | 1.01 | 0.99 | 1.01 | 1.01 | 0.85 |
| Profit before tax | 1.01 | 6.01 | 7.01 | 14.02 | 19.04 | 18.02 | 18.15 |
| Tax % | 18.1% | 29.1% | 28.1% | 30.1% | 27.1% | 17.1% | — |
| Exceptional items | 0.00 | −0.03 | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Net Profit | 0.99 | 3.99 | 4.99 | 9.99 | 13.99 | 14.99 | 14.98 |
| EPS (Rs) | — | — | — | 8.42 | 8.24 | 9.14 | 9.12 |
| Dividend payout % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — |
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| Equity Capital | 1.01 | 1.01 | 1.01 | 12.02 | 16.02 | 16.04 |
| Reserves | 4.99 | 8.99 | 13.98 | 16.98 | 64.90 | 79.88 |
| Borrowings | 2.99 | 2.99 | 3.99 | 4.98 | 29.90 | 7.97 |
| Other Liabilities | 8.99 | 21.98 | 27.97 | 26.95 | 9.99 | 6.03 |
| Total Liabilities | 17.98 | 34.97 | 46.95 | 60.93 | 122 | 111 |
| Fixed Assets | 5.99 | 7.01 | 9.99 | 9.99 | 12.01 | 14.98 |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.01 |
| Investments | 0.00 | 0.00 | 0.00 | 6.98 | 51.89 | 15.97 |
| Other Assets | 11.99 | 26.96 | 36.96 | 43.96 | 57.91 | 78.96 |
| Inventories | 0.82 | 1.08 | 11.14 | 16.08 | 21.31 | 38.54 |
| Trade receivables | 9.13 | 22.01 | 19.89 | 24.36 | 29.97 | 36.10 |
| Cash & equivalents | 0.41 | 1.56 | 0.11 | 0.13 | 0.10 | 0.09 |
| Total Assets | 17.98 | 34.97 | 46.95 | 60.93 | 122 | 111 |
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| Cash from operating activity | 1.01 | 3.01 | 4.01 | 3.01 | −23.09 | −11.03 |
| Cash from investing activity | −1.01 | −2.01 | −4.01 | −5.01 | −44.10 | 35.11 |
| Cash from financing activity | 0.00 | 0.00 | 0.00 | 1.99 | 66.94 | −23.97 |
| Net cash flow | 0.00 | 0.99 | 0.00 | 0.00 | 0.00 | 0.00 |
| Capex | 1.22 | 1.94 | 3.02 | 0.95 | 3.48 | 5.27 |
| Free cash flow | 0.00 | 1.99 | 0.99 | 1.99 | −26.94 | −15.95 |
| CFO / OP % | 103.0% | 57.0% | 72.0% | 46.0% | −120.0% | −34.0% |
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| Debtor days | 109 | 134 | 117 | 107 | 104 | 117 |
| Inventory days | 13 | 10 | 98 | 114 | 100 | 164 |
| Days payable | 119 | 140 | 215 | 144 | 26 | 24 |
| Cash conversion cycle | 3 | 4 | 1 | 77 | 178 | 258 |
| Working capital days | 9 | 14 | 27 | 58 | 72 | 258 |
| ROCE % | — | 54.9% | 46.9% | 57.0% | 26.9% | 17.9% |
For the Mar 2026 quarter, Quest Laboratories reported sales of ₹32.35 Cr, down 30.3% year on year and net profit of ₹2.86 Cr, up 48.2% year on year. The operating margin was 12.9%.
Quest Laboratories' sales for the year to Mar 2026 were ₹112 Cr; over the last twelve months they were ₹112 Cr.
Net profit for the year to Mar 2026 was ₹14.99 Cr, and ₹14.98 Cr over the last twelve months. Earnings per share over the same trailing period were ₹9.12.
Quest Laboratories reported borrowings of ₹7.97 Cr at Mar 2026, against cash and equivalents of ₹0.09 Cr.
Cash from operations was −₹11.03 Cr in the year to Mar 2026; after capital spending, free cash flow was −₹15.95 Cr.